Article Text
Abstract
Objective: To assess the opinions and practice patterns of obstetrician-gynaecologists on acceptance and use of free drug samples and other incentive items from pharmaceutical representatives.
Methods: A questionnaire was mailed in March 2003 to 397 members of the American College of Obstetricians and Gynecologists who participate in the Collaborative Ambulatory Research Network.
Results: The response rate was 55%. Most respondents thought it proper to accept drug samples (92%), an informational lunch (77%), an anatomical model (75%) or a well-paid consultantship (53%) from pharmaceutical representatives. A third (33%) of the respondents thought that their own decision to prescribe a drug would probably be influenced by accepting drug samples. Respondents were more likely to think the average doctor’s prescribing would be influenced by acceptance of the items than theirs would be (p<0.002). Respondents who distributed drug samples to patients indicated doing so because of patients’ financial need (94%) and for their convenience (76%) and less so as a result of knowledge of the efficacy of the sample product (63%). A third (34%) of respondents agreed that interactions with industry should be more strictly regulated.
Conclusion: Obstetrician-gynaecologists largely indicated that they would act in accordance with what they think is proper regarding accepting incentive items from pharmaceutical representatives. Although accepting free drug samples was considered to be appropriate more often than any other item, samples were most commonly judged to be influential on prescribing practices. The widely accepted practice of receiving and distributing free drug samples needs to be examined more carefully.
- ACOG, American College of Obstetricians and Gynecologists
- AMA, American Medical Association
- CARN, Collaborative Ambulatory Research Network
- PhRMA, Pharmaceutical Research and Manufacturers of America
Statistics from Altmetric.com
Footnotes
-
Funding: This work was supported in part by a grant from the HRSA-MCHB.
-
Competing interests: None.
Read the full text or download the PDF:
Other content recommended for you
- Perceptions of the provision of drug information, pharmaceutical detailing and engagement with non-personal promotion at a large physicians network: a mixed-methods study
- Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review
- Physicians’ intent to comply with the American Medical Association’s guidelines on gifts from the pharmaceutical industry
- Legislative, educational, policy and other interventions targeting physicians’ interaction with pharmaceutical companies: a systematic review
- Receipt and use of prohibited free samples of tobacco products among US adults who use cigarettes, cigars and smokeless tobacco, 2020
- Failure to discount for conflict of interest when evaluating medical literature: a randomised trial of physicians
- General practitioners and pharmaceutical sales representatives: quality improvement research
- Coming soon to a state near you?
- US doctors display “No drug reps” signs
- Open access to industry's clinically relevant data